BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 28792927)

  • 1. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood.
    Joung J; Engreitz JM; Konermann S; Abudayyeh OO; Verdine VK; Aguet F; Gootenberg JS; Sanjana NE; Wright JB; Fulco CP; Tseng YY; Yoon CH; Boehm JS; Lander ES; Zhang F
    Nature; 2017 Aug; 548(7667):343-346. PubMed ID: 28792927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
    Konermann S; Brigham MD; Trevino AE; Joung J; Abudayyeh OO; Barcena C; Hsu PD; Habib N; Gootenberg JS; Nishimasu H; Nureki O; Zhang F
    Nature; 2015 Jan; 517(7536):583-8. PubMed ID: 25494202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution interrogation of functional elements in the noncoding genome.
    Sanjana NE; Wright J; Zheng K; Shalem O; Fontanillas P; Joung J; Cheng C; Regev A; Zhang F
    Science; 2016 Sep; 353(6307):1545-1549. PubMed ID: 27708104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local regulation of gene expression by lncRNA promoters, transcription and splicing.
    Engreitz JM; Haines JE; Perez EM; Munson G; Chen J; Kane M; McDonel PE; Guttman M; Lander ES
    Nature; 2016 Nov; 539(7629):452-455. PubMed ID: 27783602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF
    Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.
    Li Z; Wang B; Gu S; Jiang P; Sahu A; Chen CH; Han T; Shi S; Wang X; Traugh N; Liu H; Liu Y; Wu Q; Brown M; Xiao T; Boland GM; Shirley Liu X
    Genomics Proteomics Bioinformatics; 2020 Feb; 18(1):26-40. PubMed ID: 32413516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of CRISPR/Cas9 applications for long non-coding RNA genes.
    Goyal A; Myacheva K; Groß M; Klingenberg M; Duran Arqué B; Diederichs S
    Nucleic Acids Res; 2017 Feb; 45(3):e12. PubMed ID: 28180319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.
    Kfir-Elirachman K; Ortenberg R; Vizel B; Besser MJ; Barshack I; Schachter J; Nemlich Y; Markel G
    Neoplasia; 2018 Apr; 20(4):401-409. PubMed ID: 29558679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
    Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
    Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
    Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
    [No Abstract]   [Full Text] [Related]  

  • 15. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib: the road to personalized medicine in melanoma.
    Amaria RN; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Feb; 48(2):109-18. PubMed ID: 22384451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition.
    Webster DE; Barajas B; Bussat RT; Yan KJ; Neela PH; Flockhart RJ; Kovalski J; Zehnder A; Khavari PA
    Genome Res; 2014 May; 24(5):751-60. PubMed ID: 24443471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-scale CRISPR-Cas9 knockout screening in human cells.
    Shalem O; Sanjana NE; Hartenian E; Shi X; Scott DA; Mikkelson T; Heckl D; Ebert BL; Root DE; Doench JG; Zhang F
    Science; 2014 Jan; 343(6166):84-87. PubMed ID: 24336571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.